Kallidinogenase
- Generic Name
- Kallidinogenase
- Drug Type
- Biotech
- CAS Number
- 9001-01-8
- Unique Ingredient Identifier
- OT9M1PSK9N
- Indication
适用于治疗轻至中度急性血栓性脑梗死。
Efficacy and Safety of Human Urinary Kallidinogenase for Acute Ischemic Stroke Patients Receiving Reperfusion Treatment
Not Applicable
Recruiting
- Conditions
- Acute Ischemic Stroke
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Beijing Tiantan Hospital
- Target Recruit Count
- 1204
- Registration Number
- NCT06848894
- Locations
- 🇨🇳
Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China
Study to Assess PK, Safety and Tolerability in Healthy Subjects
Phase 1
Completed
- Conditions
- Acute Ischemic Stroke
- Interventions
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Changzhou Qianhong Bio-pharma Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT06380699
- Locations
- 🇨🇳
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
Efficacy and Safety of Human Urinary Kallidinogenase Combined With Endovascular Therapy in Acute Ischemic Stroke With Large Vessel Occlusion
Not Applicable
Recruiting
- Conditions
- Acute Ischemic Stroke
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT06211712
- Locations
- 🇨🇳
Huashan Hospital, Shanghai, China
Safety and Efficacy of Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic Stroke
Not Applicable
Not yet recruiting
- Conditions
- Acute Ischemic Stroke
- Interventions
- Other: Guideline-prescribed medical therapy
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Yi Yang
- Target Recruit Count
- 986
- Registration Number
- NCT06137300
- Locations
- 🇨🇳
First Hospital of Jilin University, Changchun, Jilin, China
Effects of Human Urinary Kallidinogenase on Early Improvement and Functional Outcomes in Acute Ischemic Stroke (TK-SPEED)
Not Applicable
Not yet recruiting
- Conditions
- Acute Ischemic StrokeFunctional Outcomes
- Interventions
- Other: Clinical Routine Treatment
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Beijing Tsinghua Chang Gung Hospital
- Target Recruit Count
- 540
- Registration Number
- NCT06132880
Efficacy and Safety of Urinary Kallidinogenase in the Treatment of Acute Ischemic Stroke Combined With Type 2 Diabetes Mellitus
Not Applicable
Not yet recruiting
- Conditions
- Type 2 DiabetesAcute Ischemic Stroke
- Interventions
- Other: Placebo
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
- Target Recruit Count
- 630
- Registration Number
- NCT06085378
- Locations
- 🇨🇳
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Human Urinary Kallidinogenase Improve Short Term Motor Functional Outcome of Acute Ischemia Stroke Patients
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2021-03-01
- Lead Sponsor
- The Second Hospital of Hebei Medical University
- Target Recruit Count
- 80
- Registration Number
- NCT04102956
- Locations
- 🇨🇳
Second hospital of hebei medical university, Shijiazhuang, Hebei, China
Effects of Urinary Kallidinogenase in Acute Ischemic Stroke Patients With Abnormal Glucose Metabolism
Completed
- Conditions
- Acute Ischemic StrokeAbnormal Glucose Metabolism
- Interventions
- First Posted Date
- 2019-07-16
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- The Second Hospital of Hebei Medical University
- Target Recruit Count
- 113
- Registration Number
- NCT04020666
Evaluation Of HUK in Acute Stroke Patients: MRS and CTP
Phase 4
Completed
- Conditions
- Acute Ischemic Stroke
- Interventions
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Target Recruit Count
- 80
- Registration Number
- NCT03431909
The Metabolism Research of KLK Treating Acute Cerebral Ischemic Stroke: Focus on Drug Frequency-Efficacy Relationship
Not Applicable
- Conditions
- Cerebral Infarction
- Interventions
- First Posted Date
- 2016-06-20
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Huisheng Chen
- Target Recruit Count
- 100
- Registration Number
- NCT02806128
- Locations
- 🇨🇳
General hospital of shenyang military region, Shenyang, Liaoning, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath